| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Extreme Hodgkin's lymphoma: current problem areas
|
Proctor, S.J.
|
|
|
17 |
S4 |
p. iv15-iv17
|
article
|
| 2 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study
|
Corazzelli, G.
|
|
|
17 |
S4 |
p. iv18-iv24
|
article
|
| 3 |
Guest Editor
|
|
|
|
17 |
S4 |
p. ii-iii
|
article
|
| 4 |
Histopathology in the light of molecular profiling
|
Stein, H.
|
|
|
17 |
S4 |
p. iv5-iv7
|
article
|
| 5 |
Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention
|
Lokiec, F.
|
|
|
17 |
S4 |
p. iv33-iv36
|
article
|
| 6 |
Managing large cell lymphoma
|
Gisselbrecht, C.
|
|
|
17 |
S4 |
p. iv8-iv11
|
article
|
| 7 |
Mantle cell lymphoma: an update on management
|
Zelenetz, A.D.
|
|
|
17 |
S4 |
p. iv12-iv14
|
article
|
| 8 |
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma
|
Hertzberg, M.S.
|
|
|
17 |
S4 |
p. iv25-iv30
|
article
|
| 9 |
Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation
|
Moskowitz, C.H.
|
|
|
17 |
S4 |
p. iv37-iv39
|
article
|
| 10 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study
|
Hagberg, H.
|
|
|
17 |
S4 |
p. iv31-iv32
|
article
|
| 11 |
Table of Contents
|
|
|
|
17 |
S4 |
p. iv
|
article
|
Journal description